Pharmacokinetics and pharmacodynamics of antibiotics in otitis media

Pediatric Infectious Disease Journal

Volumn 15, Issue 10, 1996, Pages 944-948

  Reed, Michael D ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

middle ear fluid; Otitis media; pharmacodynamics; pharmacokinetics

Indexed keywords

BETA LACTAM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; MACROLIDE; PENICILLIN DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; CONFERENCE PAPER; DRUG EFFICACY; DRUG PENETRATION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OTITIS MEDIA; PRIORITY JOURNAL;

EID: 0029797320     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199610000-00032     Document Type: Conference Paper

References (32)

1. Klein JO. Antimicrobial therapy issues facing pediatricians. Pediatr Infect Dis J 1995;14:415-9.
2. Harrison CJ. Perspectives on newer oral antimicrobials: what do they add? Pediatr Infect Dis J 1995;14:436-44.
3. Drusano GL. Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother 1988;32:289-97.
4. Craig WA. Interrelationships between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995;22:89-96.
5. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996;15: 255-9.
6. Stein GE, Gurwith MJ. Amoxicillin-potassium clavulanate, a beta-lactamase-resistant antibiotic combination. Clin Pharm 1984;3:591-9.
7. Todd PA, Benfield P. Amoxicillin/clavulanic acid: an update of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1990;39:264-307.
8. Neu HC, Wilson AP, Gruneberg RN. Amoxycillin/clavulanic acid: a review of its efficacy in over 38 500 patients from 1979 to 1992. J Chemother 1993;5:67-93.
9. Reed MD, Blumer JL. Amoxicillin-potassium clavulanate; rational pharmacology meets clinical infectious disease [Editorial]. Clin Pharm 1984;3:653-4.
10. Neu HC. Amoxicillin. Ann Intern Med 1979;90:356-60.
11. Neu HC. Contribution of beta-lactamases to bacterial resistance and mechanisms to inhibit beta-lactamases. Am J Med 1985;79(Suppl 5B):2-12.
12. Moellering RC Jr. Meeting the challenges of beta-lactamases. J Antimicrob Chemother 1993;31(Suppl):1-8.
13. Caron F, Ducrotte P, Lerebours E, Colin R, Humbert G, Denis P. Effects of amoxicillin-clavulanate combination on the motility of the small intestine in human beings. Antimicrob Agents Chemother 1991;35:1085-8.
14. Adam D, Visser ID, Koeppe P. Pharmacokinetics of amoxicillin and clavulanic acid administered alone and in combination. Antimicrob Agents Chemother 1982;22:353-7.
15. Eshelman FN, Spyker DA. Pharmacokinetics of amoxicillin and ampicillin: crossover study of the effect of food. Antimicrob Agents Chemother 1978;14:539-43.
16. Staniforth DH, Clarke HL, Horton R, Jackson D, Lau D. Augmentin bioavailability following cimetidine, aluminum hydroxide and milk. Int J Clin Pharmacol Ther Toxicol 1985;23:154-7.
17. Bakken JS, Brunn JN, Gaustad P, Tasker TCG. Penetration of amoxicillin and potassium clavulanate into the cerebrospinal fluid of patients with inflamed meninges. Antimicrob Agents Chemother 1986;30:481-4.
18. Decazes JM, Bure A, Wolff M, Kitzis MD, Pangon B, Modai J. Bactericidal activity against Haemophilus influenzae of cerebrospinal fluid of patients given amoxicillin-davulanic acid. Antimicrob Agents Chemother 1987;31:2018-9.
19. Munch R, Luthy R, Blaser J, Siegenthaler W. Human pharmacokinetics and CSF penetration of clavulanic acid. J Antimicrob Chemother 1981;8:29-37.
20. Staniforth DH, Jackson D, Clarke HL, Horton R. Amoxycillin/clavulanic acid: the effect of probenecid. J Antimicrob Chemother 1983;12:273-5.
21. Nelson JD, Kusmiesz H, Shelton S. Pharmacokinetics of potassium clavulanate in combination with amoxicillin in pediatric patients. Antimicrob Agents Chemother 1982;21: 681-2.
22. Schaad UB, Casey PA, Cooper DL. Single-dose pharmacokinetics of intravenous clavulanic acid with amoxicillin in pediatric patients. Antimicrob Agents Chemother 1983;23: 252-5.
23. van Njekerk CH, van den Ende J, Hundt HKL, Louw EA. Pharmacokinetic study of a pediatric formulation of amoxycillin and clavulanic acid in children. Eur J Clin Pharmacol 1985;29:235-9.
24. Schaad UB, Casey PA, Ravenscroft AT. Pharmacokinetics of a syrup formulation of amoxycillin-potassium clavulanate in children. J Antimicrob Chemother 1986;17:341-5.
25. McCracken GH, Ginsburg CM, Clahsen JC, Thomas ML. Pharmacokinetics of cefaclor in infants and children. J Antimicrob Chemother 1978;4:515-21.
26. Faulkner RD, Yacobi A, Barone JS, Kaplan SA, Silber BM. Pharmacokinetic profile of cefixime in man. Pediatr Infect Dis J 1987;6:963-70.
27. Barr WH, Affrime M, Lin CC, Batra V. Pharmacokinetics of ceftibuten in children. Pediatr Infect Dis J 1995;14(Suppl): S93-101.
28. Saez-Llorens X, Shyu WC, Shelton S, Kumiesz H, Nelson J. Pharmacokinetics of cefprozil in infants and children. Antimicrob Agents Chemother 1990;34:2152-5.
29. Stevens RC, Reed MD, Baker DK, Shenep JL, Blumer JL, Rodman JH. Pharmacokinetics of azithromycin following single and multiple dosing in pediatric patients [Abstract]. Clin Pharmacol Ther 1996;59:143.
30. Gan VH, Chu SY, Kusmiesz HT, Craft JC. Pharmacokinetics of a clarithromycin suspension in infants and children. Antimicrob Agents Chemother 1992;36:2478-80.
31. Kearns GL, Reed MD. Clinical pharmacokinetics in infants and children: a reappraisal. Clin Pharmacokinet 1989; 17(Suppl 1):29-67.
32. Barry AL, Pfaller MA, Fuchs PC, Packer RR. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U. S. medical centers in 1992 and 1993. Antimicrob Agents Chemother 1994;38:2419-25.